In recent years, the field of cancer treatment has witnessed remarkable breakthroughs that
have revolutionized the landscape of care for cancer patients. While traditional pillars such …

Chimeric antigen receptor (CAR)-modified T cell therapy is a rapidly emerging
immunotherapeutic approach that is revolutionizing cancer treatment. The impressive …

Multiple myeloma (MM) remains a lethal hematologic cancer characterized by the expansion
of transformed plasma cells within the permissive bone marrow (BM) milieu. The emergence …

Extramedullary disease (EMD), defined as an infiltrate of clonal plasma cells at an anatomic
site distant from the bone marrow, is an uncommon manifestation of multiple myeloma. Six …

Peripheral T-cell lymphomas (PTCLs) are generally aggressive non-Hodgkin lymphomas
with poor overall survival rates following standard therapy. One-third of PTCLs express …

Despite many recent advances on cancer novel therapies, researchers have yet a long way
to cure cancer. They have to deal with tough challenges before they can reach success …

ABSTRACT Background Multiple Myeloma (MM) is a neoplastic disorder characterized by
clonal proliferation of malignant plasma cells (PCs). Flow cytometry is an essential tool to …

Multiple myeloma (MM) remains an incurable plasma cell (PC) malignancy. Although it is
known that MM tumor cells display extensive intratumoral genetic heterogeneity, an …

Background Multiple myeloma (MM) is a hematologic malignancy that is characterized by
the proliferation of abnormal bone marrow plasma cells (BMPC) and overproduction of …

Lymphoplasmacytic lymphoma (LPL) with IgG or IgA paraprotein is rare and a subset of
cases can mimic a plasma cell neoplasm (PCN). We studied 29 such cases to explore their …